EuroBiotech: More Articles of Note


> Freeline presented early clinical data on its Fabry disease gene therapy. Participants experienced a three- to four-fold increase in plasma αGLA levels. Statement  

> Alderley Park opened a 150,000-square-foot building to house tech startups. The site will enable startups working on drug discovery technologies to base themselves near to biopharma companies. Release  

> AurorA-TT, Rottapharm Biotech and Italfarmaco teamed up to create a biotech investment firm. The company, AurorA Science, will make investments of up to €5 million ($5.5 million) to support preclinical and early clinical development. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Inotrem added €5 million to its series B round. The money, coupled to a new €13 million credit line, will support a phase 2b trial in septic shock patients. Release 

> A phase 2 trial of Oculis’ diabetic macular edema drug met its efficacy endpoints. Statement 

Suggested Articles

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.

Sean Harper and Beth Seidenberg tell FierceBiotech how and why they set up their own VC firm, Westlake Village BioPartners.

Imara is looking to cap a good 2019 with an initial public offering in 2020. The rare disease biotech wants $86 million on the Nasdaq.